Fig. 6
The effects of FTY 720 treatment and blocking of IFN-γ. a Mice were injected intraperitoneally (i.p.) with FTY 720 (1 mg/kg/dose) or PBS (mock) every other day beginning 1 day before nasal immunization with HSV-2 TK−. At 1 week after immunization, the number of HSV-2-specific IFN-γ-producing cells in spleen or vagina was assessed by ELISPOT assays. Data are the representative of two independent experiments (n = 3 or 4 mice per group). **P < 0.01. N.S. not significant. b Female mice were given a single nasal inoculation of PBS as nonimmunized control or 105 PFU of live HSV-2 TK−. Mononuclear cells were isolated from CLNs 3 days after immunization and were then stained for surface CD4, CCR5, and S1P1 molecules. c Mice were treated i.p. with FTY 720 or PBS (mock) as described above. d Female C57BL/6 mice nasally immunized with HSV-2 TK− on day 0 were treated with anti-IFN-γ antibody or isotype antibody (both i.p.) on day 6, and samples were collected on day 7. c, d RT-qPCR analysis of CCL5 expression in vaginal tissues. The CCL5 mRNA expression level was normalized to that of β-actin. Values are means ± 1 SD (n = 4 mice per group). *P < 0.05. Data are representative of three (b, c) or two (d) independent experiments
